Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.
about
Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysisMortality among people with severe mental disorders who reach old age: a longitudinal study of a community-representative sample of 37,892 men.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trialObesity and coronary risk in patients treated with second-generation antipsychotics.Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profilesSudden deaths in psychiatric patientsAntipsychotic Medications and Risk of Acute Coronary Syndrome in Schizophrenia: A Nested Case-Control Study.Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical RecordExcess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services.Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Metabolic syndrome in people with schizophrenia: a review.Secondary effects of antipsychotics: women at greater risk than men.Association of depression and psychotropic medication on cardiac-related outcomes in a nationwide community-dwelling elderly population in TaiwanA meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controlsDoes antipsychotic polypharmacy increase the risk for metabolic syndrome?Metabolic syndrome in schizophrenia.Contours of usual care: meeting the medical needs of diverse people with serious mental illness.Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics.Mean Platelet Volume and Platelet Distribution Width Level in Patients with Panic Disorder.Metabolic Syndrome in First Episode Schizophrenia, Based on the National Mental Health Registry of Schizophrenia (NMHR) in a General Hospital in Malaysia: A 10-Year Retrospective Cohort Study.Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study.
P2860
Q28066750-D07BB635-31BD-4652-AD00-452076789E6CQ34435216-0C8D0CE5-0D16-49EF-82EE-0D063D19F1AEQ34623350-674D3D15-9CC4-4519-A74D-5F9072FF69E8Q35019136-CF066412-1968-496E-8DBE-D99405AF3653Q35074667-47CD6587-D4AC-4EBD-8DD1-9D8EDF8BC11BQ35577365-CD212FD8-8926-4ABD-9235-68889698B2CCQ35834580-BEA09902-F28E-4569-A84C-F089DB0CD32CQ36140777-03CB75BE-CB6A-4E1D-BB59-F26D6FE83779Q36621075-73DF7438-2B51-44E9-94C3-C6869F925E1EQ36921831-F0F3F881-E7A5-48C8-83E1-9DFF29F41A7BQ36957061-01448D2E-329B-4FEC-8BF9-EB8A65948656Q36990173-C50B5046-27E7-4A7B-AC8B-2156DE4777DBQ37016538-AF0D2EBD-4A8D-43DD-BB71-67CADD85C440Q37079080-6B24065B-4DCB-4ADC-A400-4DCB36729440Q37129646-D278CC82-415A-4B6E-A847-33E7DC011F2EQ37133664-64627860-2FD0-4E1A-8DE8-C3096A1044BDQ37165076-01AE7A47-15E6-47E3-89F1-F06909E32027Q37236162-929A1F9D-8A6D-4769-8763-944DF31A6EFDQ37281587-B2A861E5-0326-4279-8C63-60B39A287F7AQ37290165-BF2F147F-C3A9-4C16-91B0-88FE0FF4FE58Q37453862-E4D889BC-E05B-429D-82A5-DBE70389CCB4Q38599502-C4371856-1316-4113-986E-60414B62095EQ42271072-2A4EFBA3-2D74-4FD9-8E7B-DAEDCFE553DDQ55025268-8608CFCE-9092-408D-BEEC-81F0FCECD1C9Q55423163-F5B5BD99-DB1C-4CFD-9E7F-A4DEBDA3A8AB
P2860
Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Metabolic syndrome and the ris ...... eneration antipsychotic drugs.
@en
Metabolic syndrome and the ris ...... eneration antipsychotic drugs.
@nl
type
label
Metabolic syndrome and the ris ...... eneration antipsychotic drugs.
@en
Metabolic syndrome and the ris ...... eneration antipsychotic drugs.
@nl
prefLabel
Metabolic syndrome and the ris ...... eneration antipsychotic drugs.
@en
Metabolic syndrome and the ris ...... eneration antipsychotic drugs.
@nl
P2093
P1476
Metabolic syndrome and the ris ...... eneration antipsychotic drugs.
@en
P2093
Anne M Frederickson
Christoph U Correll
John M Kane
Peter Manu
P304
P577
2006-04-01T00:00:00Z